A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction
Launched by BOSTON SCIENTIFIC CORPORATION · Feb 8, 2007
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 or older
- • Clinical symptoms of biliary obstruction
- • Inoperable extrahepatic biliary obstruction by any malignant process
- • Willing and able to comply with the study procedures and provide written informed consent to participate in the study.
- Exclusion Criteria:
- • Participation in an Investigational Study within 90 days prior to date of patient consent
- • Strictures that cannot be dilated enough to pass the delivery system
- • Perforation of any duct within the biliary tree
- • Presence of a metal biliary stent
- • Presence of any esophageal or duodenal stent
- • Patients for whom endoscopic procedures are contraindicated
- • Patients with known sensitivity to any components of the stent or delivery system
- • Patients with active hepatitis or intrahepatic metastases that extensively involves both lobes of the liver
- • Patients with an anticipated life expectancy of \< 3 months
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Minneapolis, Minnesota, United States
St. Louis, Missouri, United States
Houston, Texas, United States
San Francisco, California, United States
Philadelphia, Pennsylvania, United States
Aurora, Colorado, United States
Durham, North Carolina, United States
Charlottesville, Virginia, United States
Seattle, Washington, United States
Patients applied
Trial Officials
Bret Petersen, MD
Principal Investigator
Mayo Clinic, Rochester, MN
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials